Yücel PAK, Müge AKMANSU, Fatih DEMİRCİOĞLU, Hüseyin BORA

Meme kanserli 640 hastada hormon reseptör durumu ve c-erbb-2 düzeyi ile tedavi sonuçları arası ilişki

Amaç: Çalışmada meme kanseri seyrini etkileyebilen hormon reseptördurumu ve c-erbB-2 düzeylerinin tedavi sonuçları üzerine olan etkilerisaptanmaya çalışılmıştır.Yöntemler: Küratif amaçla tedavi uygulanan 640 meme kanserli hastadagenel ve hastalıksız sağkalım verileri incelenmiştir. Ortalama takip 59,1 aydır.Hastalarda SPSS 16.0 versiyonunda Kaplan-Meier yöntemiyle genel vehastalıksız sağkalım oranları, Log-Rank testi ile prognostik faktörlerin etkileri değerlendirilmiştir.Bulgular: ER (+) ve (-) olgularda sırasıyla beş yıllık genel sağkalım oranları%85,7, %71,2 (p

The relationship between hormone receptor status and c-erbb-2 level with treatment results of 640 breast cancer patients

Objective: In this study the relevant factors that effects the treatment outcomes of patients like hormone receptor and c-erbB-2 was established. Methods: The overall and disease-free survival rates were evaluated in 640 breast cancer patients. The mean follow-up was 59,1 months. Overall and disease-free survival rates found by Kaplan-Meier method at SPSS version 16.0. Log-Rank test evaluated the prognostic factors impact. Results: In ER (+) and (-) patients 5 year overall survival rates was 85,7%, 71,2% (p

PDF

___

1. American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society, 2002.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2012. CA Cancer J Clin 2008;56:106-30.
3. Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001; 93:824-42.
4. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med 1992;326:1756-61.
5. Lim E, Metzger-Filho O, Winer EP: The natural history of hormone receptor-positive breast cancer. Oncology 2012;26:688-94, 696.
6. Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008;26:5697-704.
7. Crowe JP, Gordon NH, Hubay CA, Shenk RR, Zollinger RM, Brumberg DJ, et al. Estrogen receptor determination and long term survival of patients with carcinoma of the breast. Surg Gynecol Obstet 1991;173:273-8.
8. Harvey JN, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by IHC is superior to ligand binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
9. Pathmanathan N, Bilous AM. HER2 testing in breast cancer: an overview of current techniques and recent developments. Pathology 2012;44:587-95.
10. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, et al. Evaluation of The United States Food and Drug Administration- approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 2001;7:1669-75.
11. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, et al. HER-2 testing by local, central and reference laboratories in speciment from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24:3032-38.
12. Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA. Kinase-specific phophorylation of the estrogen receptor changes receptor interaction with ligand. Mol Endocrinol 2006;20:3120-32.
13. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998;51:227-38.
14. Elkhuizen PHM, Voogd AC, Lambert C, Tan IT, van Houwelingen HC, Leer JW, et al. Risk factors for local recurrence after breast conserving therapy for invasive carcinomas. Int J Radiat Oncol Biol Phys 1999;45:73-83.
15. Choi DH, Kim S, Rimm DL, , Carter D, Haffty BG. Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray. Cancer J. 2005;11:404-11.
16. Grills IS, Kestin L, Goldstein N, Mitchell C, Martinez A, Ingold J, et al. Risk factors for regional nodal failure after breast concerving therapy. Int J Radiat Oncol Biol Phys 2003;56:658-70.
17. Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, et al. Can patient, treatment and pathology related characteristics explain the high local recurrence rate following breast conserving therapy in young patients? Eur J Cancer 2003;39:932-44.
18. Santiago RJ, Wu L, Harris E, Fox K, Schultz D, Glick J, et al. Fifteen-year results of breast conserving surgery and definitive irradiation for stage I and II breast carcinoma. Int J Radiat Oncol Biol Phys 2004;58:233-40.
19. Pierce LJ, Griffith A, Hayman A, Douglas KR, Lichter AS. Conservative surgery and radiotherapy for stage I/II breast cancer using lung density correction. Int J Radiat Oncol Biol Phys 2005;61:1317-27.
20. Ross JC, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, et al. Targeted therapy in breast cancer the HER-2/neu gene and protein. Mol Cell Proteomics 2004;3:379-98.
21. Harris EE, Hwang T, Lee A, Cengel KA, Feldman MD, Demichele A, et al. The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conserving therapy. Breast J 2006;12:431- 6.
22. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Panel members. Meeting highligts: international expert concensus on the primary therapy on early breast cancer 2005. Ann Oncol 2005;16:1569-83.